Elusys and U.S. Army extend biodefense collaboration
Elusys has received funding from the department of Defense and the National Institutes of Health to accelerate the development of Anthim and the HP Antibody technology. In total, the Company has received over $20 million from the U.S. Government for these programs.
According to the company, Anthim is a high-affinitymonoclonal antibody, targeting the anthrax toxin Protective Antigen, that has demonstrated significant efficacy against anthrax infection in lethal animal spore challenge studies. Further, Anthim has been demonstrated to be safe and well tolerated when administered with and without antibiotics in a human safety study. Anthim is being developed for prophylaxis and post-exposure treatment of inhalation anthrax.
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.